Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 9;14:22.
doi: 10.1186/s40200-015-0137-2. eCollection 2015.

Improvement of Glucose and Lipid Profile Status With Aloe Vera in Pre-Diabetic Subjects: A Randomized Controlled-Trial

Affiliations
Free PMC article

Improvement of Glucose and Lipid Profile Status With Aloe Vera in Pre-Diabetic Subjects: A Randomized Controlled-Trial

Samaneh Alinejad-Mofrad et al. J Diabetes Metab Disord. .
Free PMC article

Abstract

Background: Pre-diabetes is a disturbing trend in the population, who are at risk of developing type-two diabetes. The aim of this study was to determine the effects use of Aloe vera in different doses on glucose and lipid profile in pre-diabetic subjects.

Methods: This study was a double blind randomized controlled trial (72 subjects) with pre-diabetes symptoms in 3 groups consumed capsules twice a day: Aloe vera 300 mg (AL300), 500 mg (AL500) and placebo (PL). Fasting blood glucose (FBS), HbA1C and lipid profile were evaluated in baseline, 4 or 8 weeks. On-way ANOVA, Friedman, Wilcoxon, Kruskal-Wallis , Mann-Whitney and Chi-square tests were used for within or between groups statistical analysis.

Results: FBS level in group AL300, showed significantly decreased in fourth week after the intervention, compared to PL in the same time (p = 0.001). Also, HbA1C level in this group at the eighth week after the intervention (p = 0.042), had a significant decrease. The levels of Total cholesterol and LDL-C, only in the group AL500 (p < 0.001 and p = 0.01), was significantly reduced, along with HDL-C level improvement just after eight weeks (p = 0.004). Triglyceride level showed a significant decrease (p < 0.045) just after four weeks use of AL500.

Conclusions: The Use of Aloe vera extract in pre-diabetic patients, could revert impaired blood glucose within four weeks, but after eight weeks could alleviate their abnormal lipid profile.

Keywords: Aloe vera; Fast blood glucose; Herbal medicine; Lipid profile; Pre-diabetis.

Figures

Figure 1
Figure 1
Flowchart of the design, groups, and the participants in the project.

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population National Health and Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29(6):1263–8. doi: 10.2337/dc06-0062. - DOI - PubMed
    1. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–90. doi: 10.1016/S0140-6736(12)60283-9. - DOI - PMC - PubMed
    1. Chen G, Liu C, Yao J, Jiang Q, Chen N, Huang H, et al. Overweight, obesity, and their associations with insulin resistance and β-cell function among Chinese: a cross-sectional study in China. Metabolism. 2010;59(12):1823–32. doi: 10.1016/j.metabol.2010.06.009. - DOI - PubMed
    1. Association AD. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3):596–615. doi: 10.2337/dc08-9017. - DOI - PubMed
    1. Cao H, Ren M, Guo L, Shang H, Zhang J, Song Y, et al. JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial. Trials. 2010;11(1):27. doi: 10.1186/1745-6215-11-27. - DOI - PMC - PubMed

LinkOut - more resources

Feedback